US Patent

US9272137 — Transdermal methods and systems for the delivery of anti-migraine compounds

Formulation · Assigned to Teva Pharmaceuticals International GmbH · Expires 2027-09-07 · 1y remaining

Vulnerability score 38/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects methods and systems for delivering anti-migraine compounds through iontophoretic patches.

USPTO Abstract

Iontophoretic patches for the delivery of anti-migraine compounds and methods of using the patches are described.

Drugs covered by this patent

sumatriptan-succinate (SUMATRIPTAN SUCCINATE)

Patent Metadata

Patent number: US9272137
Jurisdiction: US
Classification: Formulation
Expires: 2027-09-07
Drug substance claim: No
Drug product claim: Yes
Assignee: Teva Pharmaceuticals International GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.